Last $56.85 USD
Change Today +0.61 / 1.08%
Volume 604.4K
RMD On Other Exchanges
New York
As of 3:48 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

resmed inc (RMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/22/14 - $57.00
52 Week Low
02/3/14 - $41.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESMED INC (RMD)

resmed inc (RMD) Related Businessweek News

No Related Businessweek News Found

resmed inc (RMD) Details

ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders, with a focus on sleep-disordered breathing. Its products portfolio includes airflow generators, diagnostic products, mask systems, motors, and headgear, as well as other accessories, such as cold passover humidifiers, carry bags, and breathing circuits; and humidifiers comprising H5i and H4i, which connect with the continuous and variable positive airway pressure, and AutoSet flow generators to humidify and heat the air delivered to the patient to prevent the drying of nasal passages. The company also offers data communications and control products, including EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. ResMed Inc. markets its products to sleep clinics, home healthcare dealers, and third-party payers. The company sells its products through a network of distributors and direct sales force in approximately 100 countries worldwide. It has a collaboration agreement with Qualcomm Life, Inc. to develop connected health solutions based on 2net and HealthyCircles platforms. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

4,100 Employees
Last Reported Date: 08/8/14
Founded in 1989

resmed inc (RMD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $787.5K
President and Chief Operating Officer
Total Annual Compensation: $664.6K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $494.7K
President of Americas
Total Annual Compensation: $434.6K
President of Sleep-Disordered Breathing Strat...
Total Annual Compensation: $385.0K
Compensation as of Fiscal Year 2014.

resmed inc (RMD) Key Developments

ResMed Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 03:30 PM

ResMed Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 03:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

ResMed Launched the All-New S+, the First Non-Contact, Personal Sleep Monitoring Device

ResMed has recently launched the all-new S+, the first non-contact, personal sleep monitoring device. ResMed announced S+ availability through Apple retail stores in the United States and from the Apple Online Store. The free S+ by ResMed App now integrates with Apple HealthKit in iOS8 to give consumers an easy-to-read, daily snapshot of their overall health and fitness. The user report can also be shared with health care providers. S+ by ResMed sends sleep results, such as sleep patterns over time, hours slept during particular sleep cycles, and nightly sleep scores from 0 to 100, directly to Apple's Health App so the two become seamlessly integrated to give users a holistic view of their own sleep patterns and wellbeing. Should they choose to, S+ also offers consumers a quick and efficient way to share their sleep habits with physicians and healthcare providers. S+ by ResMed is now available for the suggested retail price of $149.99 at Apple, Bed Bath & Beyond(R) and Best Buy retail stores in the United States, from the Apple Online Store and online at

ResMed Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014; Provides Earnings Guidance of the Full Fiscal Year 2015

ResMed Inc. reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company increased net income 3% to $83.26 million or $0.58 per diluted share from $80.93 million or $0.56 per diluted share for the first quarter last year. Excluding the benefit of the onetime tax item noted previously, diluted earnings per share would have been $0.56, consistent with the prior year quarter. Revenue was up 6% to $380.4 million from $357.66 million a year ago. Income from operations was $94.68 million compared to $96.88 million a year ago. Income before income taxes was $101.93 million compared to $102.07 million a year ago. Net cash provided by operating activities was $86.54 million compared to $90.43 million a year ago. Purchases of property, plant and equipment were $20.68 million compared to $16.75 million a year ago. On a non-GAAP basis, diluted earnings per share was $0.01 higher at $0.59. The company provided earnings guidance of the full fiscal year 2015. Looking forward for the full fiscal year 2015, the company expects its gross margin to be in the range of 61% to 63%, assuming current exchange rates. The company estimates its effective tax rate for the full fiscal year 2015, excluding the onetime tax benefit, will be in the range of 21% to 22%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMD:US $56.84 USD +0.60

RMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $27.09 USD +0.165
IDEXX Laboratories Inc $148.64 USD +0.395
MEDNAX Inc $67.18 USD +0.14
Teleflex Inc $117.27 USD -0.28
Cooper Cos Inc/The $163.42 USD +0.55
View Industry Companies

Industry Analysis


Industry Average

Valuation RMD Industry Range
Price/Earnings 23.2x
Price/Sales 5.0x
Price/Book 4.8x
Price/Cash Flow 22.0x
TEV/Sales 4.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESMED INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at